OPTIMATA LTD

Their core work

Optimata is an Israeli SME specializing in computational and mathematical modeling of disease biology, particularly cancer. They develop simulation tools and systems medicine approaches that help researchers stratify patients and predict treatment outcomes. Across their H2020 portfolio, they have contributed computational modeling expertise to projects spanning melanoma, colorectal cancer, and stress-related disease mechanisms, consistently serving as the quantitative modeling partner within large international consortia.

What they specialise in

How they've shifted over time

Optimata's early H2020 involvement (2014-2016) centered on training networks in translational cancer research (MEL-PLEX) and fundamental disease mechanisms like ER stress (TRAIN-ERS), suggesting a broad exploratory phase. By 2018, their focus sharpened significantly toward precision oncology — the COLOSSUS project brought together computational models, multi-omics, immunomics, and patient stratification for a specific clinical application in colorectal cancer. The trajectory shows a clear move from general disease modeling toward applied precision medicine with direct clinical relevance.

Optimata is moving toward clinically actionable computational tools for precision oncology, making them a relevant partner for projects that need in silico patient stratification or treatment response prediction.

How they like to work

Optimata operates exclusively as a participant, never coordinating — consistent with a specialist SME that provides a defined technical capability (computational modeling) to larger research consortia. With 42 unique partners across 16 countries from just 3 projects, they work in large, diverse consortia rather than small focused teams. This suggests they are comfortable integrating into complex multi-partner setups and delivering modular contributions alongside academic and clinical partners.

Despite only three projects, Optimata has built a broad network of 42 partners across 16 countries, reflecting the large consortium sizes typical of MSCA training networks and RIA health projects. Their reach spans well beyond Israel into the European research ecosystem.

What sets them apart

Optimata brings a rare combination for an SME: proprietary computational modeling capabilities applied specifically to cancer biology and precision medicine. As an Israeli company embedded in European health research consortia, they bridge the strong Israeli biotech ecosystem with EU research infrastructure. For consortium builders, they offer a ready-made quantitative modeling component — the kind of specialized SME contribution that EU evaluators look for to demonstrate industry involvement and translational potential.

Highlights from their portfolio

• COLOSSUS
  Most recent and clinically focused project — applies systems medicine to metastatic colorectal cancer patient stratification, representing Optimata's clearest precision medicine application.
• MEL-PLEX
  Largest EC funding (EUR 260,301) and their first H2020 project, establishing their role as a computational modeling partner in translational melanoma research.